Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Int.biotech. (IBT) Share Price

Price 904.00p on 06-02-2026 at 19:40:07
Change -14.00p -1.53%
Buy 908.00p
Sell 902.00p
Last Trade: Sell 3,293.00 at 904.00p
Day's Volume: 132,416
Last Close: 904.00p
Open: 914.00p
ISIN: GB0004559349
Day's Range 874.00p - 914.00p
52wk Range: 480.00p - 1,000.00p
Market Capitalisation: £288.40m
VWAP: 895.41204p
Shares in Issue: 31.90m

Int.biotech. (IBT) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Sell* 3,293 904.00p Uncrossing Trade
16:35:00 - 06-Feb-26
Sell* 940 902.2448p Ordinary
16:22:10 - 06-Feb-26
Sell* 1,113 899.505p SI Trade
15:57:30 - 06-Feb-26
Buy* 108 903.68p Ordinary
15:51:10 - 06-Feb-26
Sell* 300 899.888p SI Trade
15:49:58 - 06-Feb-26
Sell* 700 901.76p SI Trade
15:45:21 - 06-Feb-26
Buy* 874 909.88p Ordinary
15:42:21 - 06-Feb-26
Sell* 8 898.00p SI Trade
15:33:10 - 06-Feb-26
Sell* 215 900.00p Automatic Execution
15:33:06 - 06-Feb-26
Sell* 500 900.00p Automatic Execution
15:33:06 - 06-Feb-26
See more Int.biotech. trades

Int.biotech. (IBT) Share Price History

Time period:
to
Date Open High Low Close Volume
6th Feb 2026 (Fri) 914.00 914.00 874.00 904.00 132,416
5th Feb 2026 (Thu) 930.00 936.00 918.00 918.00 47,121
4th Feb 2026 (Wed) 942.00 942.00 930.00 930.00 40,011
3rd Feb 2026 (Tue) 944.00 950.00 938.00 946.00 53,789
2nd Feb 2026 (Mon) 912.00 944.00 912.00 936.00 76,242
30th Jan 2026 (Fri) 930.00 930.00 914.00 918.00 83,252
29th Jan 2026 (Thu) 940.00 942.00 926.00 930.00 97,993
28th Jan 2026 (Wed) 952.00 956.00 940.00 940.00 70,909
27th Jan 2026 (Tue) 954.00 962.00 950.00 954.00 61,176
26th Jan 2026 (Mon) 974.00 974.00 950.00 958.00 106,789
23rd Jan 2026 (Fri) 992.00 994.00 980.00 980.00 83,485
22nd Jan 2026 (Thu) 980.00 990.00 972.00 982.00 56,370
21st Jan 2026 (Wed) 964.00 970.00 962.00 970.00 40,180
20th Jan 2026 (Tue) 950.00 964.00 942.00 964.00 82,263
19th Jan 2026 (Mon) 960.00 964.00 952.00 960.00 103,581
16th Jan 2026 (Fri) 966.00 974.00 964.00 970.00 64,502
15th Jan 2026 (Thu) 970.00 986.00 966.00 972.00 67,590
14th Jan 2026 (Wed) 962.00 968.00 956.00 968.00 76,946
13th Jan 2026 (Tue) 964.00 966.00 954.00 954.00 69,060
12th Jan 2026 (Mon) 970.00 976.00 956.00 968.00 85,003
9th Jan 2026 (Fri) 976.00 986.00 968.00 986.00 137,977
8th Jan 2026 (Thu) 974.00 980.00 968.00 968.00 90,166
7th Jan 2026 (Wed) 948.00 972.00 944.00 970.00 111,724
See more Int.biotech. price history

Int.biotech. (IBT) Regulatory News

Date Source Headline
6th Feb 2026 12:13 pm RNS-R Virtual Outlook Presentation
6th Feb 2026 11:50 am RNS Net Asset Value(s)
5th Feb 2026 11:36 am RNS Net Asset Value(s)
4th Feb 2026 11:44 am RNS Net Asset Value(s)
3rd Feb 2026 11:56 am RNS Net Asset Value(s)
2nd Feb 2026 11:58 am RNS Net Asset Value(s)
30th Jan 2026 11:56 am RNS Net Asset Value(s)
29th Jan 2026 5:26 pm RNS-R QuotedData's In The HotSeat Special
29th Jan 2026 11:36 am RNS Net Asset Value(s)
28th Jan 2026 2:06 pm RNS Director/PDMR Shareholding
See more Int.biotech. regulatory news

Int.biotech. (IBT) Share News

UK dividends calendar - next 7 days

16th Jan 2026 15:52

Read More

UK dividends calendar - next 7 days

22nd Dec 2025 14:43

Read More

International Biotechnology beats benchmark with 0.7% NAV gain

6th Nov 2025 19:17

(Alliance News) - International Biotechnology Trust PLC on Thursday said its portfolio continued to outperform the sector benchmark as the company reported full-year results. Read More

IN BRIEF: International Biotechnology Trust notes Novo to buy Akero

9th Oct 2025 15:40

International Biotechnology Trust PLC - investor in biotech and life science companies - Notes portfolio firm Akero Therapeutics Inc as agreed to be taken over by Novo Nordisk AS in a deal worth up to EUR5.2 billion. Novo Nordisk will pay an initial USD54 per share, with a contingent portion of the deal worth USD6 per share. The Bagsvaerd, Denmark-based pharmaceuticals company will pay an initial EUR4.7 billion to buy the firm, and a potential additional payment of EUR500 million, hinging on US regulatory approval for key Akero treatment Efruxifermin. The deal adds Akero's Efruxifermin to Novo Nordisk's portfolio. The asset is aimed at treating metabolic dysfunction-associated steatohepatitis, a disease caused by fat buildup in the liver. Read More

International Biotechnology to raise unquoted exposure with Schroders

2nd Oct 2025 13:31

(Alliance News) - International Biotechnology Trust PLC on Thursday said it has partnered with Schroders Capital to access more investees in the earlier stages of development. Read More

See more Int.biotech. news
FTSE 100 Latest
Value10,369.75
Change60.53

Login to your account

Forgot Password?

Not Registered